A flow chemistry approach to norcantharidin analogues

Letters in Drug Design and Discovery

Volumn 8, Issue 6, 2011, Pages 568-574

  Tarleton, Mark ^a   Young, Kelly A ^a   Unicomb, Elli ^b   McCluskey, Siobhann N ^b   Robertson, Mark J ^a   Gordon, Christopher P ^a   McCluskey, Adam ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Lambton High School   (Australia)

Author keywords

Cantharidin; Flow chemistry; Flow hydrogenation; Norcantharidin; Protein phosphatase inhibition

Indexed keywords

3 (4 METHOXYBENZYLCARBAMOYL) 7 OXABICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 3 (BENZYLCARBAMOYL) 7 OXABICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 3 (ETHOXYCARBONYL) 7 OXABICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 3 (METHOXYCARBONYL) 7 OXABICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; AMIDE; ESTER DERIVATIVE; NORCANTHARIDIN; UNCLASSIFIED DRUG;

ARTICLE; FLOW KINETICS; HYDROGENATION; ONE POT SYNTHESIS; PRIORITY JOURNAL; RING OPENING; SCALE UP;

EID: 79959361516     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/157018011795906730     Document Type: Article

References (21)

1. DiMasi, J. A. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoecon. 2002, 20, 1-10.
2. Colombo, M.; Peretto, I. Chemistry strategies in early drug discovery: an overview of recent trends. Drug Discov. Today 2008, 13, 677-684.
3. McCluskey, A.; Sim, A. T. R.; Sakoff, J. A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 2002, 45, 1151-1175 (Pubitemid 34263552)
4. McCluskey, A.; Sakoff, J. A. Small Molecule inhibitors of serine / threonine protein phosphatases. Mini Rev. Med. Chem. 2001, 1, 43-55
5. Sakoff, J. A.; McCluskey, A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Cur. Pharm. Des. 2004, 10, 1139-1159. (Pubitemid 38425896)
6. Bagu, J. R.; Sykes, B. D.; Craig, M. M.; Holmes, C. F. B. A molecular basis for different interactions of marine toxins with protein phosphatase-1. Molecular models for bound motuporin, microcystins, okadaic acid, and calyculin A. J. Biol. Chem. 1997, 272, 5087-5097. (Pubitemid 27090064)
7. Sheppeck, J. E.; Gauss, C. M.; Chamberlin, A. R. Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins. Bioorg. Med. Chem. 1997, 5, 1739-1750. (Pubitemid 27423732)
8. Hill, T. A.; Stewart, S. G.; Gordon, C. P.; Ackland, S. P.; Gilbert, J.; Sauer, B.; Sakoff, J. A.; McCluskey, A. Norcantharidin Analogues: Synthesis, Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition. ChemMedChem. 2008, 3, 1878-1892
9. Tatlock, J. H.; Linton, A.; Hou, X. J.; Kissinger, C. R.; Pelletier, L. A.; Showalter, R. E.; Tempczyk, A.; Villafranaca, J. E. Structurebased design of novel calcineurin (PP2B) inhibitors Bioorg. Med. Chem. Lett. 1997, 7, 1007-1012 (Pubitemid 27193356)
10. 1, and 2B Bioorg. Med. Chem. Lett. 1997, 7, 1833-1836 (Pubitemid 27317798)
11. Laidley, C. W.; Dauben, W. G.; Guo, Z. R.; Lam, J. Y. L.; Casida, J. E. 2-Carboxymethylendothal analogues as affinity probes for stabilized protein phosphatase 2A. Bioorg. Med. Chem. 1999, 7, 2937-2944. (Pubitemid 30105867)
12. Bajsa, J.; McCluskey, A.; Gordon, C. P.; Stewart, S. G.; Hill, T. A.; Sahu, R.; Duke, S. O.; Tekwani, B. L. The antiplasmodial activity of norcantharidin analogues that may act by protein phosphatase inhibition. Bioorg. Med. Chem. Lett. 2010, 20, 6688-6695.
13. Stork, G.; van Tamelen, E. E.; Friedman, L. J.; Burgstahler, A. W. A Stereospecific Synthesis of Cantharidin J. Am. Chem. Soc. 1953, 75, 384-392.
14. Dauben, W. G.; Kessel, C. R.; Kazuo, H.; Takemura, K. H. Simple, efficient total synthesis of cantharidin via a high-pressure Diels- Alder reaction. J. Am. Chem. Soc. 1980, 102, 6893-6894.
15. Sakoff, J. A.; Ackland, S. P.; Baldwin, M. L.; Keane, M. A.; McCluskey, A. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Investig. New Drugs 2002, 20, 1-11. (Pubitemid 34251646)
16. th December 2010.
17. Clapham, B.; Wilson, N. S.; Michmerhuizen, M. J.; Blanchard, D. P.; Dingle, D. M.; Nemcek, T. A.; Pan, J. Y.; Sauer, D. R. Construction and validation of an automated flow hydrogenation instrument for application in high-throughput organic chemistry. J. Comb. Chem. 2008, 10, 88-93.
18. McCluskey, A.; Bowyer, M. C.; Collins, E.; Sim, A. T. R.; Sakoff, J. A.; Baldwin, M. L. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg. Med. Chem. Lett. 2000, 10, 1687-1690. (Pubitemid 30495241)
19. In a typical library development study 25 mg of compound is required for complete chemical characterisation and biological evaluation. At 1 mL/min a 0.05M solution reaction produces ca 10 mg/min (assumes average MW of product ̃ 350 and a 60% purified yield). Thus a 5 minute flow chemistry run affords ca 50 mg of pure analogue. The equivalent batch process requires 24 hrs.
20. Hart, M. E.; Chamberlin, A. R.; Walkom, C.; Sakoff, J. A.; McCluskey, A. Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg. Med. Chem. Lett. 2004, 14, 1969-1973. (Pubitemid 38410875)
21. Baxendale, I. R.; Deeley, J.; Griffiths-Jones, C. M.; Ley, S. V.; Saaby, S.; Geoffrey K. Tranmer, G. K. A flow process for the multi-step synthesis of the alkaloid natural product oxomaritidine: a new paradigm for molecular assembly. Chem. Commun. 2006, 2566-2568.